PDE5 inhibitors: Looking beyond ED

International Journal of Clinical Practice

Volumn 57, Issue 3, 2003, Pages 159-160

  Jackson, Graham ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MECHANISM; EDITORIAL; ENDOTHELIUM LESION; ERECTILE DYSFUNCTION; FOREARM BLOOD FLOW; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SEXUAL BEHAVIOR; VASCULAR SMOOTH MUSCLE; VASODILATATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CARDIOVASCULAR DISEASES; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; VASODILATION;

EID: 0037396510     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-254.
2. Gillies HC, Roblin D, Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 2002; 86: 131-141.
3. Jackson G. Phosphodiesterase type 5 inhibition in cardiovascular disease: experimental models and potential clinical applications. Eur Heart J Suppl 2002; 4(suppl H): H19-H23.
4. Katz SD, Balidemaj K, Homma S et al. Acute type 5-phosphodiesterase inhibition with sildenafil enhances flow mediated vasodilatation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-851.
5. DeSouza C, Parulkar A, Lumpkin D et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336-1339.
6. Halcox JPJ, Nour KA, Zalos G et al. The effect of sildenafil on human vascular function platelet activation and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-1240.
7. Jackson G, Chambers J. Sildenafil for primary pulmonary hypertension: short and long-term symptomatic benefit. Int J Clin Pract 2002; 56: 397-398.
8. Katz S. Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. CHF 2003; 9: 9-15.
9. Mahmud A, Hennessey M, Feely J. Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 2001; 15: 707-713.
10. Haneda M, Kikkawa R, Maeda S et al. Dual mechanism of angiotensin II inhibits ANP-inducted mesangial cGMP accumulation. Kidney Int 1991; 40: 188-194.
11. Jaarsma T. Sexual problems in heart failure patients. Eur J Cardiovasc Nurs 2002; 1: 61-67.
12. Fogari R, Zoppi A, Poletti L et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. J Hypertens 2002; 14: 27-31.
13. Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon. Arthritis Rheum 2001; 56: 282-283.
14. Giuliano F. Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J Suppl 2002; 4(suppl H): H7-H12.